Search Results

Integrated Biosciences today announced they have joined Illumina Ventures Labs to integrate the company’s drug discovery engine with Illumina sequencing.

Tome Biosciences, Inc., the programmable genomic integration company, presented preclinical data highlighting its progress in developing PGI as integrative gene and cell therapies at ASGCT’s 27th Annual Meeting in Baltimore, MD.

Integrated Biosciences announced a strategic partnership with the patient-led Project 8p Foundation to enhance the treatment landscape for chromosome 8p duplication, deletion and inverted duplication deletion disorders.

Tome Biosciences, Inc., the programmable genomic integration company, has launched to usher in a new era of genomic medicines based on programmable genomic integration.

Tome Biosciences, Inc. today announced that it will present preclinical data on its PGI technologies, integrase-mediated PGI (I-PGI) and ligase-mediated PGI (L-PGI), at ASGCT’s 27th Annual Meeting taking place May 7-11 in Baltimore, MD.

Sanguine Biosciences announced advanced capabilities in acquiring and integrating electronic health records with donor specimens, further advancing its commitment to empowering patients to participate in medical research.

Life sciences companies Integrated DNA Technologies (IDT) and Element Biosciences, Inc. have bolstered their partnership with products to enable more efficient and streamlined next generation sequencing (NGS) workflows for users of the AVITI System, an innovative sequencing and multi-omics platform based on Element’s novel avidity base chemistry.

Tome Biosciences, Inc. today announces the issuance of US Patent 11,952,571 for “Systems, Methods, and Compositions for Site-Specific Genetic Engineering Using Programmable Addition via Site-Specific Targeting Elements (PASTE)” by the US Patent and Trademark Office.

Pressure BioSciences Signs Definitive Agreement to Acquire Uncle Bud’s, Forward Integrating PBIO’s UltraShear Platform into Multiple Markets.